Subscribe

Articles

Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
By Lisa A. Raedler, PhD, RPh, Medical Writer
Drug Profiles
2017 Second Annual Oncology Guide to New FDA Approvals
Chronic lymphocytic leukemia (CLL), a cancer of B-cell lymphocytes, is the most common type of leukemia in adults. According to the American Cancer Society, more than 18,900 Americans will be diagnosed with CLL in 2016. Read More ›
Smoking Cessation and Lung Cancer
Smoking Cessation and Lung Cancer
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon discusses the importance of smoking cessation programs for patients diagnosed with lung cancer. Read More ›
Screening for Lung Cancer
Screening for Lung Cancer
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon talks about the best approaches for screening patients for lung cancer. Read More ›
Who Should be Screened for Lung Cancer?
Who Should be Screened for Lung Cancer?
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon identifies the target population for lung cancer screening. Read More ›
Common Presenting Factors for NSCLC
Common Presenting Factors for NSCLC
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon provides an overview of the most common presenting clinical features in adults with non-small cell lung cancer (NSCLC). Read More ›
Shifts in Lung Cancer Treatment
Shifts in Lung Cancer Treatment
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon reviews how certain drugs can change the landscape for treating patients with lung cancer. Read More ›
A Look at PD-1 and PD-L1 Inhibitors
A Look at PD-1 and PD-L1 Inhibitors
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer. Read More ›
ALK Gene Rearrangement and PD-L1 Expression
ALK Gene Rearrangement and PD-L1 Expression
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement. Read More ›
Differences in NSCLC Patient Populations
Differences in NSCLC Patient Populations
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data. Read More ›
Choosing the Right Therapy for Patients with NSCLC
Choosing the Right Therapy for Patients with NSCLC
By Edward Garon, MD
Lung Cancer, Video
Videos
Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice. Read More ›

Page 181 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.